
Sign up to save your podcasts
Or


This episode was released in February 2021, and is being re-shared to offer the research behind the popular weight loss drugs Ozempic and Wegovy. Northwestern's Robert Kushner, MD, discusses the drug semaglutide, typically prescribed for treatment of Type 2 diabetes and the results of the phase 3 clinical trial as a treatment for obesity with very promising results. The study was published in the New England Journal of Medicine, and in 2022, Kushner was awarded the prestigious Herbert Pardes Clinical Research Excellence Award from the Clinical Research Forum.
By Northwestern University Feinberg School of Medicine4.9
2424 ratings
This episode was released in February 2021, and is being re-shared to offer the research behind the popular weight loss drugs Ozempic and Wegovy. Northwestern's Robert Kushner, MD, discusses the drug semaglutide, typically prescribed for treatment of Type 2 diabetes and the results of the phase 3 clinical trial as a treatment for obesity with very promising results. The study was published in the New England Journal of Medicine, and in 2022, Kushner was awarded the prestigious Herbert Pardes Clinical Research Excellence Award from the Clinical Research Forum.

90,963 Listeners

21,898 Listeners

43,594 Listeners

91 Listeners

6,456 Listeners

112,191 Listeners

5 Listeners

56,577 Listeners

0 Listeners

10,283 Listeners

33 Listeners

3,037 Listeners

8,203 Listeners

29,240 Listeners

1,590 Listeners

4,300 Listeners

7 Listeners

633 Listeners

12,343 Listeners